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Background: Osteoprotegerin (OPG), a potent inhibitor of osteoclastogenesis, decreases bone
resorption and has protective effects on bone mineral density (BMD). Recently we have shown
that the adipose-tissue derived OPG relates to BMD in patients with chronic obstructive pulmo-
nary disease (COPD), a condition associated with increased risk of osteoporosis.
Objective: Here we aimed to investigate the potential of circulatory OPG to reflect hip BMD in
patients with COPD.
Patients and methods: In 56 subjects with COPD [age, 61.7  6.7 years; forced expiratory vol-
ume in 1 s (FEV1), 53.6  19.2% predicted], total femur BMD was assessed by dual energy X-ray
absorptiometry, serum OPG and b-crosslaps, a marker of increased bone resorption, by
commercially available assays.
Results: From patients with normal hip BMD (n Z 32, T-score 0.1  0.8) to those with osteo-
penia (nZ 14, T-score 1.6  0.4) and osteoporosis (nZ 10, T-score 3.4  0.7) serum OPG
levels significantly increased (6.6  1.8 versus 7.2  2.9 and versus 8.6  1.5 pmol/l,
pZ 0.036). In addition, hip T-scores were directly related to FEV1, and inversely to b-crosslaps
(R Z 0.40, p Z 0.002; R Z 0.38, p Z 0.01, respectively). In multivariate analysis, OPG inde-
pendently predicted hip T-scores after adjustments for age, gender, FEV1, and b-crosslaps
(p Z 0.011, adjusted R2 Z 0.354). Area under receiver operator curve for OPG as a discrimi-
nator of osteoporosis was 0.787 (95% CI, 0.653e0.921) (p Z 0.005).
Conclusions: Present results suggest that osteoporosis of the hip is associated with increased
circulatory levels of OPG in patients with COPD. OPG might serve as a biomarker of this
COPD-related comorbidity.
ª 2013 Elsevier Ltd. All rights reserved.5 615 2665; fax: þ421 55 615 2664.
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622 P. Pobeha et al.IntroductionChronic obstructive pulmonary disease (COPD) represents
one of the leading causes of mortality worldwide, and
moreover, hospitalizations associated with this condition
result into a significant burden to health-care resources [1].
Nevertheless, increased morbidity in patients with COPD is
not entirely due to pulmonary complications; a substantial
proportion of adverse outcomes result from COPD-related
systemic effects and comorbidities including coronary heart
disease, cachexia, muscle dysfunction, and osteoporosis [2].
Reduced bone mineral density (BMD) is highly prevalent
in patients with COPD, affecting 9e69% of subjects in
different cohorts [3]. Nevertheless, pathological processes
involved in the increased risk of COPD-related osteoporosis
are poorly understood. Our recent study suggested that
adipokines including the adipose-tissue derived osteopro-
tegerin (OPG) relate to BMD in patients with COPD, and
appear to act as mediators between fat mass and BMD [4].
Nevertheless, there are no literary data on the potential of
circulatory OPG to reflect BMD in such patients.
The receptor activator of nuclear factor kB (RANK)
pathway has been identified to play a central role in bone
remodeling and disorders of mineral metabolism. The inter-
action of RANKwith its ligand (RANKL)was shown to stimulate
the formation and activation of osteoclasts in conjunction
with various cytokines and calciotropic hormones. OPG, an
anti-inflammatory protein derived from osteoblasts inhibits
osteoclastogenesis and reducesbone resorption by acting as a
decoy receptor to competitively inhibit RANKL [5]. Imbalance
between RANKL and OPG, one of the major pathogenetic
factors of osteoporosis, is most likely triggered by systemic
inflammation induced by COPD [6]. Indeed, in the Bergen
COPD Cohort Study increased plasma OPG levels were asso-
ciated with the severity of the disease reflected by the fre-
quency of exacerbations and severity of respiratory
impairment, conditions known to correlate with systemic
inflammation [7], thus rising an intriguing question whether
circulatory OPG levels relate to BMD in patients with COPD.
Nevertheless, BMD was not measured in the Bergen Cohort
Study, and two further investigations yielded inconclusive
results: on onehand a linkbetween lumbar vertebral BMDand
circulatory RANKL but notOPGwas observed inCOPDpatients
[8], on the other hand OPG was related to hip but not lumbar
BMD in mild-to moderate COPD [9]. The latter study did not
include patients with severe and very severe COPD. Impor-
tantly, circulatory OPG was previously found to be related to
hip but not lumbar BMD in terminal stages of disorders other
than COPD such as advanced chronic heart or renal failure
[10,11]. Therefore, the purpose of the present study was to
investigate serum OPG and RANKL levels in relation to oste-
oporosis of the hip across all stages of COPD severity.
Methods
Subjects
This is a prospective cross-sectional study in patients with
diagnosis of COPD according to the Global initiative for
chronic Obstructive Lung Disease (GOLD) recommendations
[1], free from exacerbation for 8 weeks who wereconsecutively recruited from two out-patient clinics affili-
ated with the university hospital setting. The study inclu-
sion criteria required the patients to be clinically stable,
performing regular mild physical activity, and receiving an
adequate and balanced diet. Exclusion criteria were: use of
systemic corticosteroids, treatment with long-term home
oxygen therapy, respiratory disorders other than COPD,
known malignancy, and any concomitant endocrine, rheu-
matoid, kidney, liver or gastrointestinal tract disease that
was capable to interfere with bone metabolism and mineral
density. None of the patients had previous diagnosis of
osteoporosis nor had been treated with bone-targeted
medications. Dyspnea severity was evaluated using the
Modified Medical Research Council (MMRC) scale [12].
On the investigation day, each subject completed a fast-
ing blood sample collection, pre-bronchodilator and post-
bronchodilator spirometry and bodyplethysmography, and
measurements of BMD. Information regarding COPD exacer-
bations in the preceding year, comorbidities and medication
use was retrieved from patients’ charts of the referring
physicians. The study had approval of the Ethics Committee
of the L. Pasteur University Hospital, Kosice, Slovakia, and all
subjects gave written consent to the study.
Pulmonary function tests
Pulmonary function tests were assessed with the use of
bodyplethysmography (Ganshorn, Germany) in accordance
with European Respiratory Society standards [13]. Tests were
performed with patients in a sitting position by the same
technician in order to ensure consistency of the technique.
Three technically acceptablemeasurementswere performed
in each patient, and the highest value was included in the
analyses. COPDdiagnosis andairflowobstruction severitywas
evaluated on the basis of the GOLD recommendations [1].
Bone mineral density and body composition
BMD and body composition were measured by dual energy
X-ray absorptiometry (DEXA) with fan-beam technology
using a total body scanner (Lunar Prodigy, GE Healthcare,
United Kingdom). Individual measurements of the left hip
(total femur), antero-posterior lumbar spine (L1 to L4), and
total body BMD were expressed in absolute values in grams
of mineral per unit area scanned (g/cm [2]) and relative T-
scores. This score represents the difference in SDs from
mean reference BMD values that have been matched for
race and sex from peak bone mass. Calibration was per-
formed routinely every morning using the standard pro-
vided by the manufacturer. Coefficient of variation during
measurement of standard phantom was less than 1%. The
diagnosis of hip osteoporosis was established according to
the recommendations of the World Health Organization [14]
for a specific measurement site. Body weight and fat free
mass was adjusted for height squared to calculate body
mass index (BMI) and fat free mass index (FFMI).
Biochemical analyses
In all patients, peripheral venous blood samples from the
antecubital vein were collected between 7.00 and 8.00 a.m.
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sessments were performed at the day of collection. At the
time of venous blood samples collection, arterial blood sam-
ple was obtained by puncture of radial artery to determine
arterial oxygen tension (PaO2) and arterial carbon dioxide
tension (PaCO2). Samples used to assess the serum levels of C-
reactive protein (CRP), inflammatory cytokines, bone turn-
overmarkers, OPG and RANKL,were stored at - 80 C until the
day of the analyses. High-sensitivity serum CRP levels were
assessed by immunoturbidimetric method (Randox, United
Kingdom). The analytical sensitivity of this CRP assay is
0.1 mg/l. Serum tumor necrosis factor-a and interleukin-6
levels were measured using commercially available enzyme-
linked immunosorbent assay kits (Beckmann-Coulter Immu-
notech). Bone turnover markers osteocalcin and total type 1
amino-terminal propeptide of procollagen (P1NP) reflecting
bone formation, and C-terminal cross-linking telopeptides of
type I collagen (b-crosslaps) reflecting bone resorption [15]
were assessed using the electrochemiluminiscence immuno-
assays (Roche, Germany). Serum OPG and total RANKL levels
were determined by enzyme-linked immunosorbent assays
using commercially available kits for OPG (Biomedica,
Austria) and total RANKL (Immundiagnostik, Germany). As-
says were performed according to manufacturers’ protocols.Statistical analyses
Statistical analyses were performed using SPSS software
version 14.0 (SPSS Inc., USA). The KolmogoroveSmirnov test
of normality was applied. Differences between groups in
normally distributed variables were tested by one-way
analysis of variance (ANOVA) with all-pairwise comparisons
using the Holm-Sidak method. Differences between groups
in non-normally distributed variables were tested by Krus-
kaleWallis ANOVA on ranks and Dunn’s test was used for all-
pairwise comparisons. Fisher exact test was used to
compare the proportion of categorical variables between
groups. Least-squares linear regression analysis was used to
assess the unadjusted relationships between hip T-score as
the dependent variable, and pulmonary functions, body
composition parameters, and bone serum markers. Pearson
product-moment correlation coefficient (R) is reported to
show the degree of linear relationship between variables. In
the multivariate analysis, a multiple linear regression model
was used with hip T-score as the dependent variable, and
age, gender, forced expiratory volume in 1 s (FEV1), and
bone serum markers as independent variables. Coefficient
of determination (R2) is reported to indicate the model fit,
and percentage of variance of the dependent variable
explained by the predictors included in the final model.
Non-normally distributed variables were log-transformed
before entering the regression analyses. Receiver operator
characteristic (ROC) analysis was used to examine the
discriminator performance of OPG in predicting hip T-score
equal to or lower than a cut-off value for osteoporosis. The
area under ROC curve and associated 95% confidence in-
tervals (CI) were used as indicators of the overall accuracy
of identifying positive cases of osteoporosis.
A p value of<0.05was considered statistically significant.
Continuous variables are shown asmeans SD, non-normally
distributed variables as median (interquartile range).Results
Patient characteristics
Fifty six patients with COPD (52 men and 4 women) were
enrolled. They were generally late middle-aged (mean age
61.7  6.7 years) with a mean 36.6  20.7 pack years his-
tory of smoking. Patients were divided into three groups
according to the presence of the hip osteoporosis: the first
one was formed by 32 (57.1%) patients with normal hip
(total femur) BMD (T-score 1), the second by 14 (25.0%)
patients with osteopenia (T-score <1 and >2.5), and the
third by 10 (17.9%) patients with osteoporosis (T-score
2.5). Table 1 displays demographic data, respiratory
symptoms, comorbidities and body composition parameters
in the three respective groups. No differences were
observed in age, gender proportion, smoking history, COPD
duration or dyspnea severity scores between the groups. No
differences were observed between the groups in the pro-
portion of patients with coronary artery disease or type 2
diabetes. Two patients had previous myocardial infarction;
one with normal hip BMD and one with osteopenia. The
proportion of patients with arterial hypertension was the
lowest among patients with osteoporosis (p < 0.05). Pa-
tients with osteoporosis had significantly reduced BMI,
FFMI, and fat mass percentage compared to patients with
normal BMD or osteopenia (p < 0.05 for both comparisons).
Table 2 displays parameters of bone density, and Table 3
pulmonary function tests and arterial blood gases in the
three groups of patients. Patients with osteoporosis had
significantly lower FEV1, FEV1/forced vital capacity (FVC)
ratio, and higher residual volume (RV)/total lung capacity
(TLC) ratio compared to those with normal BMD or osteo-
penia (p Z 0.002; p Z 0.002; p Z 0.007; respectively).
Serum levels of b-crosslaps and osteocalcin significantly
increased from patients with normal BMD to those with
osteopenia and osteoporosis (p Z 0.025; p Z 0.017;
respectively) (Table 4). In contrast, no differences were
observed between the groups in the neutrophil count, serum
CRP, inflammatory cytokines, or thyroid and parathyroid
hormone levels. In univariate analyses, hip T-score was
directly related to FEV1, and both BMI and FFMI (R Z 0.40,
p Z 0.002; R Z 0.61, p < 0.001; R Z 0.57, p < 0.001;
respectively), and inversely to RV and RV/TLC ratio, and to
log transformed serum b-crosslaps (R Z 0.38, p Z 0.004;
RZ 0.35, pZ 0.007; RZ 0.35, pZ 0.01; respectively).
Serum OPG and RANKL concentrations and hip BMD
Serum levels of OPG significantly increased from patients
with normal hip BMD to those with osteopenia and osteo-
porosis (6.6  1.8 versus 7.2  2.9 and versus
8.6  1.5 pmol/l; respectively, P for trend Z 0.036). In
multiple pair-wise comparisons, serum OPG levels were
significantly higher in patients with osteoporosis compared
to patients with normal hip BMD (Fig. 1). No differences
were observed in RANKL levels between the three groups
[0.82 (0.43, 1.23) versus 0.91 (0.37, 3.63) and versus 1.56
(0.46, 3.93) mg/l; respectively, p Z 0.534].
A significant inverse relationship was seen between
plasma OPG, and both BMI and FFMI (R Z 0.32, p Z 0.016;
Table 1 Patient characteristics.
Variable Entire cohort Normal BMD Osteopenia Osteoporosis P value
Patients, No (%) 56 32 (57.1) 14 (25.0) 10 (17.9)
Age, yr 61.7  6.7 61.2  6.7 60.8  6.7 64.7  6.3 0.289
Male gender, No. (%) 52 (91.2) 31 (96.9) 13 (92.9) 8 (80.0) 0.195
Packyears 36.6  20.7 36.4  23.1 39.7  18.8 32.4  15.5 0.492
Duration of COPD, yr. 6.3  7.4 5.9  5.8 4.6  6.4 10.3  12.0 0.285
MMRC grade 1.4  0.7 1.4  0.7 1.2  0.7 1.8  0.6 0.158
Borg score 2.8  2.0 2.6  1.7 2.5  2.2 3.7  2.5 0.277
Arterial hypertension, No. (%) 32 (57.1) 22 (68.8) 8 (57.1) 2 (20.0) 0.025
Coronary artery disease, No. (%) 12 (21.4) 6 (18.8) 3 (21.4) 3 (30) 0.751
Type 2 diabetes, No. (%) 7 (12.5) 5 (15.6) 2 (14.3) 0 (0.0) 0.416
BMI, kg/m2 27.3  6.8 28.9  5.6 27.1  7.1 19.5  2.9*y ˂0.001
FFMI, kg/m2 18.4  2.4 19.2  2.0 18.1  2.6 16.1  1.1*y <0.001
FM (%) 29.6  11.3 33.3  8.7 30.9  10.3 16.2  10.4*y ˂0.001
Values are given as the mean  SD. *p < 0.05 versus normal BMD; yp < 0.05 versus osteopenia.
BMD e bone mineral density; COPD e chronic obstructive pulmonary disease; MMRC e Modified Medical Research Council scale; BMI e
body mass index; FFMI e fat-free mass index; FM e fat mass.
Table 2 Measurements of hip (total femur), lumbar spine, and total BMD.
Variable Entire cohort Normal BMD Osteopenia Osteoporosis P value
Hip BMD, g/cm2 0.9  0.2 1.0  0.1 0.8  0.1 0.6  0.1*y ˂0.001
Hip, T-score 1.0  1.5 0.1  0.8 1.6  0.4 3.4  0.7*y ˂0.001
Lumbar spine BMD, g/cm2 1.1  0.3 1.2  0.2 1.0  0.3 0.7  0.1*y ˂0.001
Lumbar spine, T-score 1.3  1.7 0.4  1.4 1.8  1.0 3.5  0.6*y ˂0.001
Total BMD, g/cm2 1.1  0.2 1.2  0.1 1.1  0.1* 0.9  0.1*y ˂0.001
Total T-score 1.2  1.8 0.2  1.2 1.7  0.8* 3.8  1.2*y ˂0.001
Values are given as the mean  SD. *p < 0.05 versus normal BMD; yp < 0.05 versus osteopenia.
BMD e bone mineral density.
624 P. Pobeha et al.R Z 0.35, p Z 0.008; respectively). In contrast, no such
relationships were observed between RANKL levels and BMI
or FFMI. Also there were no relationships between plasma
OPG and RANKL levels or between OPG or RANKL levels and
pulmonary function parameters or bone turnover markers
(data not shown).
In multivariate linear analysis with age, gender, FEV1,
log-transformed b-crosslaps, and serum OPG levels as in-
dependent variables, only FEV1, b-crosslaps, and plasma
OPG independently predicted hip T-score (adjustedTable 3 Pulmonary functions.
Variable Entire cohort Normal BMD
FEV1, l 1.6  0.6 1.8  0.6
FEV1, % predicted 53.6  19.2 58.3  19.0
FEV1/FVC ratio 48.5  12.2 51.3  11.1
RV, l 4.0  1.0 3.8  0.8
TLC, l 7.3  1.4 7.2  1.4
RV/TLC ratio 55.2  9.3 53.2  8.2
PaO2, kPa 9.25  1.58 9.70  1.70
PaCO2, kPa 5.10  0.82 5.16  0.78
SaO2, % 93.0  4.3 94.0  3.8
Values are given as the mean  SD. *p < 0.05 versus normal BMD; yp
BMD e bone mineral density; FEV1 e forced expiratory volume in 1 s; F
capacity; PaO2 e partial pressure of oxygen; PaCO2 e partial pressurR2Z 0.354, Table 5). Area under the ROC curve for OPG as
a discriminator of hip T-score 2.5 was 0.787 (95% CI,
0.653e0.921) (p Z 0.005).Discussion
The present study provides a novel observation on the
increased circulatory OPG in COPD-related osteoporosis,
and its potential to serve as a biomarker of reduced hip BMDOsteopenia Osteoporosis P value
1.7  0.6 0.9  0.3*y <0.001
56.1  17.1 35.1  11.3*y 0.002
50.4  10.2 36.6  12.2*y 0.002
4.0  0.92 4.73  1.59 0.211
7.5  1.4 7.3  1.7 0.784
54.1  8.4 63.3  3.2*y 0.007
9.08  1.04 8.11  1.23* 0.016
4.84  0.76 5.29  0.98 0.632
93.3  2.1 89.8  6.3* 0.011
< 0.05 versus osteopenia.
VC e forced vital capacity; RV e residual volume; TLC e total lung
e of carbon dioxide; SaO2 e oxygen saturation in hemoglobin.
Table 4 Serum markers of bone turnover and inflammatory and endocrine parameters.
Variable Entire cohort Normal BMD Osteopenia Osteoporosis P value
CRP, mg/l 5.0(5.0, 8.0) 5.0(5.0, 6.1) 5.2(3.3, 7.6) 6.5(5.0, 17.1) 0.210
Neutrophil count, 109/l 4.4  1.4 4.2  1.1 4.4  1.5 5.1  2.1 0.277
IL-6, pg/ml 3.6(2.9, 6.9) 3.6(2.8, 9.1) 3.5(2.7, 4.9) 4.6(3.1, 6.9) 0.653
TNF-a, pg/ml 13.4(10.7, 16.5) 14.3(12.1, 22.1) 12.3(11.0, 14.4) 9.3(8.3, 13.8) 0.134
Osteocalcin, pg/ml 18.2(13.6, 24.0) 16.7(13.9, 22.9) 16.6(11.8, 20.7) 27.3(19.1, 34.4) 0.017
b-crosslaps,mg/l 0.26(0.14, 0.47) 0.24(0.14, 0.36) 0.23(0.12, 0.48) 0.67*(0.38, 0.84) 0.025
P1NP, mg/l 31.7(24.5, 46.7) 29.4(24.5, 41.5) 31.0(18.5, 35.2) 50.2(26.9, 77.6) 0.125
Parathormone, pmol/l 30.1(5.2, 46.4) 26.7(4.9, 42.4) 9.5(5.2, 51.0) 40.7(23.1, 47.6) 0.637
TSH, IU/l 1.78(1.15, 2.31) 1.78(1.23, 2.20) 2.07(1.08, 2.83) 1.31(0.51, 1.96) 0.246
fT4, pmol/l 15.6(14.1, 17.2) 15.4(14.0, 17.2) 16.0(14.8, 16.8) 16.8(14.2, 18.2) 0.885
Values are given as median (interquartile range). *p < 0.05 versus normal BMD.
BMD e bone mineral density; CRP e high sensitivity C-reactive protein; IL-6 e interleukin-6; TNF-a e tumor necrosis factor-a; P1NP e
type 1 amino-terminal propeptide of procollagen; TSH e thyroid-stimulating hormone; fT4 e free thyroxine.
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with osteoporosis of the hip have increased serum OPG
levels that predict the total femur T-score independently of
age, gender, markers of bone resorption and of the degree
of airflow limitation. In previous reports increases in OPG
were associated with the severity of COPD [7], and related
to hip but not lumbar spine BMD in mild-to-moderate COPD
[9]. Nevertheless, to the best of our knowledge our data are
the first to demonstrate that increases in circulatory OPG
levels reflect also concurrent development of osteoporosis
in patients with COPD.
Osteoporosis is a systemic skeletal disease characterized
by decreased bone mineral content and microarchitectural
deterioration. A recent meta-analysis of 13 studies in pa-
tients with COPD indicated the overall mean prevalence of
osteoporosis of 35%, ranging from 9 to 69% in different co-
horts [3]. In agreement, osteoporosis was diagnosed in 18%
of consecutively recruited out-patients with COPD in the
present study. Clinical correlates of osteoporosis in COPD
include low BMI and body composition measures, reductions
in pulmonary function, and therapy with systemic cortico-
steroids [16e18]. In our cohort, use of systemic cortico-
steroids represented an exclusion criterion, and thereforeFigure 1 Plasma osteoprotegerin (OPG) levels in patients
with chronic obstructive pulmonary disease and different
femur bone mineral density (BMD) categories. *p < 0.05.such therapy did not interfere with results of the present
study. Importantly, patients with osteoporosis in the pre-
sent cohort had low pulmonary functions as reflected by
reductions in FEV1, in accordance with previous reports
[18e20].
Improvements in understanding of pathological pro-
cesses involved in the process of bone loss in COPD are
highly warranted since osteoporosis has serious conse-
quences in such patients. Not only are hip fractures highly
prevalent among patients with COPD, they also result in a
twofold increased risk of post-operative pulmonary com-
plications [21]. Several mechanisms likely underlie the
increased risk of low BMD in patients with COPD, such as
systemic inflammation, decreased physical activity owing
to dyspnea, and/or other factors leading to proteolysis,
reduced bone formation and increased bone resorption
[22,23]. OPG, an anti-inflammatory protein derived from
osteoblasts, is a soluble member of the tumor necrosis
factor receptor superfamily that inhibits osteoclastogenesis
by acting as a decoy receptor to competitively inhibit
RANKL, and thus preventing the interaction of RANKL with
its receptor RANK [24]. In our previous study we observed
relationships between adipose tissue leptin and OPG ex-
pressions and measures of BMD among patients with COPD
[4]. Nevertheless, circulatory OPG levels were not
measured and, indeed, the question regarding serum OPG
and osteoporosis in patients with COPD across all stages of
the disease severity has not been previously approached.
The only recent study by Duckers et al. [9] did not include
patients with very severe (GOLD IV) COPD, and conse-
quently only two patients in their cohort suffered from hip
osteoporosis. Therefore, our observations on increased
serum OPG levels among COPD patients with osteoporosis
complement and extend these previous findings in several
ways. First, although Duckers et al. [9] speculated about a
link between OPG and bone resorption markers in COPD, we
have demonstrated that OPG levels predicted total femur
T-score independently of bone resorption as reflected by
the lack of an association between OPG and b-crosslaps in
either univariate or multivariate analyses. Second, our
observations point at a possible role of OPG as a biomarker
of osteoporosis in COPD. This could be clinically meaning-
ful, since in the recent guidelines for the management of
Table 5 Multiple linear regression analysis with femur T-score as a dependent variable.
Variable b coefficient SE Standardized b coefficient 95% Confidence interval P value
Intercept 1.984 2.011 e 5.997 to 1.983 0.329
Age 0.005 0.027 0.023 0.057 to 0.048 0.849
Gender 0.782 0.656 0.137 0.527 to 2.080 0.239
FEV1 0.023 0.009 0.300 0.005 to 0.041 0.015
Log b-crosslaps 1.541 0.554 0.341 2.627 to 0.508 0.008
OPG 0.214 0.081 0.315 0.377 to 0.054 0.011
SE e standard error of b coefficient; FEV1 e forced expiratory volume in 1 s; OPG e osteoprotegerin.
626 P. Pobeha et al.COPD, patients with this condition represent a target group
for treatment of osteoporosis [1]. Importantly, our obser-
vation of increased circulatory OPG in patients with oste-
oporosis is in agreement with other chronic diseases with
different disease-specific mechanisms of bone loss such as
chronic heart failure [10] or end-stage kidney failure [11].
Since OPG is a protein with protective effects against bone
loss it has been speculated that its increases in such clinical
conditions may represent a mechanism that counter-acts
disease-specific mechanisms of increased bone loss such
as systemic inflammation [6] or increased tissue break-
down and proteolysis [7].
Osteoblasts and stromal cells in the skeletal tissue
secrete OPG which in its soluble state blocks the RANK/
RANKL interaction [5,6], and thereby acts as a physiological
regulator of (increased) bone turnover. In general, skeletal
tissue represents the main source of circulatory OPG levels
[24]. Indeed, our former findings of reduced fat-tissue OPG
expressions in patients with COPD and osteoporosis [4]
combined with the results of the present study suggest
that adipose-tissue does not substantially contribute to
circulatory OPG levels in COPD.
No relationships were observed between serum RANKL
levels and hip or lumbar BMD in COPD patients in the pre-
sent study, in contrast to previous report [8]. Nevertheless,
severe concerns might have been raised in the interpreta-
tion of the serum RANKL levels in that study since the
proportion of membrane-bound RANKL may vary consider-
ably and a certain percentage of patients may even have
undetectable RANKL levels in the systemic circulation [25].
Indeed, this was the case in one patient in our cohort.
Interestingly, circulatory OPG was related to hip but not
lumbar osteoporosis in our study, in agreement with pre-
vious reports in terminal stages of disorders other than
COPD such as chronic heart [10] or renal failure [11]. Dif-
ferences in bone composition and in the pattern of BMD loss
between the hip and lumbar spine [26] may underlie this
discrepancy. In addition, among patients with COPD,
physical deconditioning and reduction in weight-bearing
demands exert greater effects on the hip than on the
lumbar spine, [3,9] thus contributing to the progression of
hip osteoporosis rather than to lumbar BMD loss.
There are some limitations in the present study such as
its cross-sectional nature that does not allow for revealing
causal relationships between OPG and osteoporosis. Lon-
gitudinal studies to evaluate the time course of OPG levels
changes in association with measurements of BMD are
warranted. Furthermore, limited number of patients and a
small number of women represent another limitation.However, circulatory OPG levels in the present study were
comparable to those seen previously in COPD [9] and
chronic heart failure patients [10], and the observed in-
creases in circulatory OPG (w30%) in osteoporotic COPD
patients parallel those reported in patients with osteopo-
rosis in other advanced chronic diseases [10,11]. We
therefore believe that our results are robust to gain some
understanding on the role of OPG in COPD-related osteo-
porosis. Also, it has to be underlined that concomitant
measurements, within one group of patients with COPD, of
body composition, BMD, and of circulatory OPG and RANKL
levels are unique and represent strength of the study.
In conclusion, our results suggest that osteoporosis is
associated with increased circulatory levels of OPG in pa-
tients with COPD, and therefore OPG might serve as a
biomarker of this COPD-related comorbidity. Further
studies are needed to analyze the interactions between
OPG and complex processes of bone resorption in more
details.
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